TELA Bio faces Nasdaq delisting over bid price; plans hearing and reverse split

TELA Bio, Inc.

Nasdaq notified TELA Bio on 9/15/26 it is subject to delisting for failing $1.00 minimum bid price rule.
Company intends to request a Nasdaq Hearings Panel hearing, which will stay any suspension pending outcome.
Filed proxy for reverse stock split (1-for-5 to 1-for-15) to regain bid price compliance; special meeting 10/8/26.
No assurance stockholders approve reverse split; delisting risk persists if not approved or price not sustained.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.